Lista de obras - Alexis B Cortot - Dominio Público Uruguay

Afatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer--Letter.

artículo científico publicado en 2016

Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey.

artículo científico publicado en 2018

Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: a retrospective study.

artículo científico publicado en 2013

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)

scientific article published on 14 August 2019

Cancer screening in France: 10 years of analysis of behaviours by the EDIFICE surveys

artículo científico publicado en 2017

Castleman's disease: unusual presentation of Castleman's disease and review of literature ⬇️

artículo científico publicado el 29 de enero de 2013

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial

artículo científico publicado en 2019

Current and Former Smokers: Who Wants To Be Screened?

scientific article published on 06 July 2018

Defining the "Frequent Exacerbator" Phenotype in COPD: A Hypothesis-Free Approach

artículo científico publicado en 2017

Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer

artículo científico publicado en 2017

EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy.

artículo científico publicado en 2009

EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)

artículo científico publicado en 2010

Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers

artículo científico publicado en 2017

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

artículo científico publicado en 2018

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

artículo científico publicado en 2017

Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis

article

Feasibility of assessing EGFR mutation and others using samples obtained by EBUS transbronchial needle aspiration

artículo científico publicado en 2013

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

artículo científico publicado en 2017

Frequent and less frequent paraneoplastic syndromes in lung cancer ⬇️

artículo científico publicado el 1 de enero de 2013

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de [...]

artículo científico publicado en 2012

High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study

scientific article published on 09 October 2019

Higher predictive value of tumour and node [18F]-FDG PET metabolic volume and TLG in advanced lung cancer under chemotherapy

artículo científico publicado en 2014

Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study

artículo científico publicado en 2013

Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy: Comparison of the Prognostic Ability of RECIST 1.1, an Alternate Method (Crabb), and Image Heterogeneity Analysis

artículo científico publicado en 2015

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

artículo científico publicado en 2019

Improvement of refractory rheumatoid arthritis-associated constrictive bronchiolitis with etanercept

scientific article published on 01 April 2005

In which context is physician empathy associated with cancer patient quality of life?

artículo científico publicado en 2018

Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.

artículo científico publicado en 2017

Le dépistage individuel du cancer broncho-pulmonaire en pratique. Perspectives sur les propositions du groupe de travail pluridisciplinaire de l’Intergroupe francophone de cancérologie thoracique, de la Société d’imagerie thoracique et du Gro

artículo científico publicado en 2014

Les exacerbations de l’asthme de l’adulte en questions

artículo científico publicado en 2010

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

artículo científico publicado en 2016

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

artículo científico publicado en 2013

M14K and M38K malignant pleural mesothelioma cell lines preserve the same claudin-based phenotype in vivo.

artículo científico publicado en 2013

MET amplification increases the metastatic spread of EGFR-mutated NSCLC

scientific article published on 11 September 2018

MET exon 14 mutation, new target in lung sarcomatoid carcinoma

artículo científico publicado en 2015

MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering

artículo científico publicado en 2017

Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas?

artículo científico publicado en 2016

Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients

scientific article published on 07 September 2018

Osimertinib (Tagrisso®): Activity, indication and modality of use in non-small cell lung cancer

artículo científico publicado en 2016

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.

artículo científico publicado en 2017

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

artículo científico publicado en 2017

P14.11 Determination of the EGFR mutations including T790M in the cerebrospinal fluid of patients with leptomeningeal metastasis from EGFR mutant non small cell lung cancer.

artículo científico publicado en 2017

PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells.

artículo científico publicado en 2015

Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history

scientific article published on 01 June 2007

Perception of Lung Cancer Risk: Impact of Smoking Status and Nicotine Dependence.

artículo científico publicado en 2018

Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy.

artículo científico publicado en 2013

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial

scientific article published on 01 October 2019

Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study.

artículo científico publicado en 2006

Physician Empathy Interacts with Breaking Bad News in Predicting Lung Cancer and Pleural Mesothelioma Patient Survival: Timing May Be Crucial

artículo científico publicado en 2018

Preferential Localization of MET Expression at the Invasion Front and in Spreading Cells Through Air Spaces in Non-Small Cell Lung Carcinomas

artículo científico publicado en 2017

Profiles of caregivers most at risk of having unmet supportive care needs: Recommendations for healthcare professionals in oncology

scientific article published on 03 October 2019

Prospective Validation Obtained in a Similar Group of Patients and with Similar High Throughput Biological Tests Failed to Confirm Signatures for Prediction of Response to Chemotherapy and Survival in Advanced NSCLC: A Prospective Study from the Eur

artículo científico publicado en 2014

Pulmonary MALT lymphoma revealing AIDS

artículo científico publicado en 2006

Randomized phase II trial evaluating treatment with EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial

scientific article published on 06 March 2020

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation

scientific article published on 27 November 2018

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.

artículo científico publicado en 2018

Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study.

artículo científico publicado en 2018

Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice

scientific article published on 26 February 2019

Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC

artículo científico publicado en 2018

Specificities of resectable Stage III non-small-cell lung cancer

scientific article published on 01 November 2004

Systemic treatment of brain metastases from lung cancer

artículo científico publicado en 2015

The multiple paths towards MET receptor addiction in cancer.

artículo científico publicado en 2018

[A difficult diagnosis]

article

[A difficult end of life]

artículo científico publicado en 2009

[Confidentiality in medical practice: tell no one]

artículo científico publicado en 2009

[Guidelines of clinical practice made by the European Lung Cancer Working Party: updates]

artículo científico publicado en 2014

[MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer]

artículo científico publicado en 2018

[Malignant pleural mesothelioma: diagnosis and treatment]

artículo científico publicado en 2013

[Should elevated beta-HCG levels be an exclusion criteria in clinical trials? A case report of paraneoplastic secretion associated with lung adenocarcinoma]

scientific article published on 18 January 2013

[Tumour assessment criteria for immune checkpoint inhibitors]

scientific article published on 27 August 2018

[Which treatments should be proposed in resectable stage III cancers?]

scientific article published on 01 November 2004

c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas

scientific article published on 24 August 2018

Lista de obras de Alexis B Cortot

Afatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer--Letter.

Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey.

Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: a retrospective study.

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)

Cancer screening in France: 10 years of analysis of behaviours by the EDIFICE surveys

Castleman's disease: unusual presentation of Castleman's disease and review of literature ⬇️

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial

Current and Former Smokers: Who Wants To Be Screened?

Defining the "Frequent Exacerbator" Phenotype in COPD: A Hypothesis-Free Approach

Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer

EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy.

EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)

Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.

Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis

Feasibility of assessing EGFR mutation and others using samples obtained by EBUS transbronchial needle aspiration

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

Frequent and less frequent paraneoplastic syndromes in lung cancer ⬇️

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de [...]

High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study

Higher predictive value of tumour and node [18F]-FDG PET metabolic volume and TLG in advanced lung cancer under chemotherapy

Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study

Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy: Comparison of the Prognostic Ability of RECIST 1.1, an Alternate Method (Crabb), and Image Heterogeneity Analysis

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Improvement of refractory rheumatoid arthritis-associated constrictive bronchiolitis with etanercept

In which context is physician empathy associated with cancer patient quality of life?

Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.

Le dépistage individuel du cancer broncho-pulmonaire en pratique. Perspectives sur les propositions du groupe de travail pluridisciplinaire de l’Intergroupe francophone de cancérologie thoracique, de la Société d’imagerie thoracique et du Gro

Les exacerbations de l’asthme de l’adulte en questions

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

M14K and M38K malignant pleural mesothelioma cell lines preserve the same claudin-based phenotype in vivo.

MET amplification increases the metastatic spread of EGFR-mutated NSCLC

MET exon 14 mutation, new target in lung sarcomatoid carcinoma

MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering

Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas?

Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients

Osimertinib (Tagrisso®): Activity, indication and modality of use in non-small cell lung cancer

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

P14.11 Determination of the EGFR mutations including T790M in the cerebrospinal fluid of patients with leptomeningeal metastasis from EGFR mutant non small cell lung cancer.

PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells.

Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history

Perception of Lung Cancer Risk: Impact of Smoking Status and Nicotine Dependence.

Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy.

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial

Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study.

Physician Empathy Interacts with Breaking Bad News in Predicting Lung Cancer and Pleural Mesothelioma Patient Survival: Timing May Be Crucial

Preferential Localization of MET Expression at the Invasion Front and in Spreading Cells Through Air Spaces in Non-Small Cell Lung Carcinomas

Profiles of caregivers most at risk of having unmet supportive care needs: Recommendations for healthcare professionals in oncology

Prospective Validation Obtained in a Similar Group of Patients and with Similar High Throughput Biological Tests Failed to Confirm Signatures for Prediction of Response to Chemotherapy and Survival in Advanced NSCLC: A Prospective Study from the Eur

Pulmonary MALT lymphoma revealing AIDS

Randomized phase II trial evaluating treatment with EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.

Real-life feasibility of home-based pulmonary rehabilitation in chemotherapy-treated patients with thoracic cancers: a pilot study.

Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice

Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC

Specificities of resectable Stage III non-small-cell lung cancer

Systemic treatment of brain metastases from lung cancer

The multiple paths towards MET receptor addiction in cancer.

[A difficult diagnosis]

[A difficult end of life]

[Confidentiality in medical practice: tell no one]

[Guidelines of clinical practice made by the European Lung Cancer Working Party: updates]

[MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer]

[Malignant pleural mesothelioma: diagnosis and treatment]

[Should elevated beta-HCG levels be an exclusion criteria in clinical trials? A case report of paraneoplastic secretion associated with lung adenocarcinoma]

[Tumour assessment criteria for immune checkpoint inhibitors]

[Which treatments should be proposed in resectable stage III cancers?]

c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas